A recent study reveals that individuals who stop using popular weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who end traditional diet and exercise plans.
Research printed in a major health publication demonstrates that while obese people often shed substantial amounts of their total mass while using the jabs, the mass returns at an average rate of nearly a kilo each month upon discontinuation.
"Users buying such treatments must be aware of the danger of fast weight regain when the therapy ends," stated lead investigator Dr. Susan Jebb.
Such speed of recovery suggests a return to pre-treatment weight within about a year and a half.
Analyzing Therapies
The study, which reviewed 37 of studies involving thousands of patients, compared the effects of GLP-1 agonists with other pills.
Researchers emphasize that individuals who shed pounds through lifestyle changes alone usually have a less rapid creep back—perhaps 0.1 kg a month—once they finish.
Understanding the Fast Rebound
Doctors believe the mechanism of the jabs is key to understanding the amplified rebound.
The injections mimic a body's own chemical called GLP-1, which helps regulate feelings of fullness.
"Artificially providing GLP-1 concentrations far above than normal might result in the system to generate a reduced amount of its own natural GLP-1, and may also lessen responsiveness to its actions," noted Dr. Adam Collins, a dietetics specialist.
"Stopping of this medication leads to appetite is uncontrolled, making excessive eating a significant risk."
An Ongoing Condition?
The NHS suggest the jabs for people with obesity-related health risks, alongside recommended diet and exercise modifications.
A number of clinicians contend that, given the significant potential of relapse, the therapy should be considered life-long.
This view is reinforced by pharmaceutical companies, who state that the results "emphasize the long-term nature of excess weight," comparing it to managing conditions like high blood pressure.
User Experiences
Users who have come off the jabs report a powerful return of hunger.
"It felt as if a switch activating and I was suddenly ravenous," described a patient.
This challenge is worsened if patients have not adopted sustainable lifestyle or habit modifications during treatment.
Growing Use
Survey data show that a significant number of people in the UK have used these injections in the past year, with demand remaining high.
- Use is higher among females compared to males.
- The 40s and 50s demographic shows the highest usage rates.
- Many access the medications through private healthcare rather than public health services.
In conclusion, clinicians stress that while the jabs are effective agents for shedding pounds, they are not a permanent fix and long-term success hinges on integrated behavioural management.
